Taisho Pharmaceutical Holdings Co Ltd - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of this webpage for potential risks for Taisho Pharmaceutical Holdings Co Ltd based on sector, geography and size. If you work at Taisho Pharmaceutical Holdings Co Ltd and you would like to licence your Sustainability aseessment, please contact us. Full ESG assessment of Taisho Pharmaceutical Holdings Co Ltd can be reached by signing up for free.
Taisho Pharmaceutical Holdings Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 1.3, social score of 1.1 and governance score of 1.3.
1.2
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1755 | TRACON Pharmaceuticals Inc | 1.3 | Low |
| 1755 | Trimurthi Ltd | 1.3 | Low |
| 1779 | Taisho Pharmaceutical Holdings Co Ltd | 1.2 | Low |
| 1779 | Cell Biotech Co Ltd | 1.2 | Low |
| 1779 | Aurisco Pharmaceutical Co Ltd | 1.2 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Taisho Pharmaceutical Holdings Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd offer flexible work?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose water use targets?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Taisho Pharmaceutical Holdings Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Taisho Pharmaceutical Holdings Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Taisho Pharmaceutical Holdings Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose its waste policy?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose energy use targets?
Sign up for free to unlockDoes Taisho Pharmaceutical Holdings Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Taisho Pharmaceutical Holdings Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Taisho Pharmaceutical Holdings Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.